MedTech Dive January 9, 2024
The company also shared earnings expectations for 2024 at the J.P. Morgan Healthcare Conference.
Dive Brief:
- Dexcom plans to launch a new continuous glucose monitor this summer for people with Type 2 diabetes who don’t take insulin.
- The device, called Stelo, was submitted to the Food and Drug Administration for review in the fourth quarter of 2023.
- Dexcom CEO Kevin Sayer said Monday at the J.P. Morgan Healthcare Conference that the company will start with cash pay for Stelo and will “eventually seek reimbursement.”
Dive Insight:
Dexcom has been talking for months about plans to make a CGM for people who don’t take insulin. At the J.P. Morgan Healthcare Conference, company executives shared more details as...
Today's Sponsors
Today's Sponsor